You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS

    SBC: NOVORON BIOSCIENCE INC            Topic: NINDS

    7. Project Summary Multiple sclerosis (MS) is a neurodegenerative disease in which myelin of the central nervous system (CNS) is destroyed by a self-reactive immune response. This demyelination is accompanied by the death of the myelinating cells themselves, the oligodendrocytes. Repeated bouts of demyelination leave the denuded CNS neurons vulnerable to degradation and is the major cause of neuro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Novel monoclonal antibody for single dose treatment of acute CNS injury

    SBC: Oncosynergy, Inc.            Topic: 999

    PROJECT SUMMARY Traumatic brain injury (TBI) represents a significant societal and economic impact. To date, there are no FDA- approved pharmacotherapies to prevent or reverse TBI. The standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamics. The patient may undergo surgery to remove hematomas, repair skull fractures, and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. A user-friendly scalable microfluidic platform for enhanced neuron-cell culture

    SBC: Xona Microfluidics, Inc.            Topic: NIMH

    DESCRIPTION (provided by applicant): Neuron-cell culture is widely used for studies in basic research, drug discovery, and toxicity testing. Traditional random cultures allow limited access to subcellular compartments (axons, dendrites, synapses) due to extensive and haphazard growth of neurons. Our long-term goal is to provide robust, user-friendly, and cost effective culture platforms that can o ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Targeting lipid rafts for treatment of migraine

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NINDS

    PROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.

    SBC: Douleur Therapeutics Inc            Topic: NINDS

    Project Summary AbstractUpwards ofmillion individuals are afflicted by chronic pain in the US alonewithmillion of these individuals suffering from neuropathic painOn a global scalechronic pain affectsbillion individualswithwho endure lower back painFrom a clinical perspectivethe International Association for the Study of Pain approximates thatinpatients present with painand on an annual basisinpat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Advancing clemizole for hepatitis C: towards a pre-IND package

    SBC: EIGER GROUP INTERNATIONAL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Evaluation of Staphylococcus aureus agr-based Quorum Sensing as Vaccine Candidate

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our passive vaccination strategies targeting Staphylococcus aureus/MRSA to prevent or treat infections associated with S. aureus/MRSA. With the emergence of highly antibiotic-resistant bacterial strains, most notably MRSA, new approaches for combating bacterial infections are desperately nee ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Modulation of the Innate Immune System by Fisetin for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most prevalent age-associated disease and growing evidence suggeststhat aspects of the innate immune system play a major role its progression. Based on this evidence, we propose a new approach to the treatm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government